by 
The Wilson’s Disease Treatment Market is estimated to be valued at US$ 560.2 Mn or in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Wilson’s disease is a rare, autosomal recessive inherited disease of copper metabolism characterized by abnormal accumulation of copper in the liver, central nervous system, and other organs. Symptoms of this condition consist of liver disease, neurological symptoms such as tremors and Parkinson-like movement disorders, and psychiatric problems. Standard treatment includes chelating agents such as penicillamine and trientine, which help remove excess copper from the body by forming complexes with copper that can be excreted in the urine. Zinc supplements are also used as they prevent copper absorption from the gastrointestinal tract.
Market Dynamics:
Increasing diagnosis rate of Wilson’s disease across major markets due to rising awareness about the disease and availability of advanced diagnostic techniques is expected to drive the market growth over the forecast period. According to National Organization for Rare Diseases (NORD), the estimated prevalence of Wilson’s disease is around 1 in 30,000 worldwide. However, the exact incidence is unknown due to underdiagnosis or misdiagnosis of the condition. Furthermore, increasing research and development activities for development of novel drugs for treatment of Wilson’s disease is also expected to boost the market growth. For instance, Valeant Pharmaceuticals International, Inc. and Tsumura & Co. are conducting various clinical trials to develop new drug candidates for treatment of Wilson’s disease. However, lack of approved drugs and limited treatment options are some of the factors that may hinder the market growth.
Segment Analysis
The global Wilson’s Disease Treatment market is segmented based on therapy, distribution channel, and region. By therapy, the penicillamine segment dominated the market in 2022 due to its extensive first-line usage in treating Wilson’s disease. By distribution channel, hospital pharmacies accounted for the largest share owing to high patient preference for hospital-based care.
PEST Analysis
Political: Government support for research on rare diseases like Wilson’s has increased over years, driving market growth.
Economic: Rising healthcare expenditure in developing nations has augmented the demand for advanced treatment options.
Social: Increasing awareness initiatives by patient advocacy groups regarding early disease diagnosis and management are boosting the market.
Technological: Advancements in gene-based therapies offer promising alternatives for refractory Wilson’s disease in future.
Key Takeaways
The global Wilson’s Disease Treatment market is expected to witness high growth, exhibiting CAGR of 6.3% over the forecast period, due to increasing research focus on developing novel treatment paradigms. Regionally, North America held the largest share in 2023 driven by high occurrence of Wilson’s disease and well-established healthcare infrastructure. Europe was the second largest regional market stimulated by rising government funding for orphan disease research. Key players operating in the Wilson’s Disease Treatment market are Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck & Co., Inc., VHB Life Science Ltd., Teva Pharmaceuticals USA, Inc., and Tsumura & Co.
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc.
